Stanford



Rajni Agarwal

Professor of Pediatrics (Stem Cell Transplantation)

Pediatrics - Stem Cell Transplantation

CLINICAL OFFICE (PRIMARY)

- **Pediatric Stem Cell Transplantation**

  725 Welch Rd Ste 200

  Palo Alto, CA 94304

  Tel (650) 497-8953 **Fax** (650) 724-1164

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

  Elizabeth Alarcon - Administrative Associate

  Email elarcon@stanford.edu

  Tel (650) 725-9250

Bio

CLINICAL FOCUS

- Blood and Marrow Transplantation, Pediatric
- Cell and Gene therapy
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Pediatrics - Stem Cell Transplantation
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Clinical Director, Pediatric Stem Cell Transplant, (2008- present)
- Section chief, Pediatric Stem Cell Transplantation, (2010- present)

HONORS AND AWARDS

- Fanconi Anemia Appreciation award, Fanconi Anemia Research Fund (October 2023)
- DISTINGUISHED SERVICE AWARD, STANFORD CHILDREN'S HEALTH/LUCILE PACKARD CHILDRENS HOSPITAL (MAY14, 2018)
- President's award, Best Woman Candidate in India in Medical School Examinations (1979)

PROFESSIONAL EDUCATION

- Board Certification: Pediatrics, American Board of Pediatrics (2024)
- Residency: Cincinnati Children's Hospital Medical Center Pediatric Residency (1995) OH
- Residency: MGM Medical College (1983) India
- Medical Education: MGM Medical College (1983) India
- Internship: MGM Medical College (1981) India
- MD, Indore University , Pediatrics (1983)
- M.B.B.S, Indore University (1980)

COMMUNITY AND INTERNATIONAL WORK

- Crescent Zakat Fund, Children's hospital at Stanford
- Binns Program for Cord Blood Research, Children's hospital at Stanford
- volunteer donor recruitment for bone marrow transplants

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I am a highly trained Pediatric stem cell transplant physician with a strong basic science background and experience with translational research. I trained extensively in India and premier institutions in USA as a pediatric Hematologist-Oncologist and transplant physician. My experience in this field also includes extensive expertise in development of stem cell assays and in vivo models of human hematopoiesis .

I started the clinical Umbilical cord blood transplant program at Cincinnati Children's. Through my research efforts we were able to develop a sterile system for collection and use of cord blood cells. This endeavor later contributed in establishing methods to collect and store cord blood for clinical use. In the laboratory we were able to set up the assays to identify and collect highly purified hematopoietic cells from the cord blood. The engraftment and expansion potential of the cord blood derived hematopoietic cells was studied in the immune deficient mice. These models were then used to develop assays for gene transfer in Fanconi Anemia.

Currently, I have been at Stanford university and Children's hospital at Stanford for the past 23 years and served as the medical director and section chief of Pediatric Stem Cell Transplant program until 2019.

My focus is entirely clinical and translational research to reduce toxicity from high doses of conditioning chemotherapy and radiation therapy, cellular therapies to reduce graft vs host disease, graft manipulation to reduce complications from graft vs. host disease in patients who receive mismatched donor stem cells and gene therapy for genetic disorders like IPEX and Fanconi Anemia.

I have expertise in phase I clinical trial design and implementation in cell and gene therapies. I have written, implemented and lead 6 phase 1 clinical trials at Stanford in the past 8 years.

My most innovative clinical Trial is reducing toxicity from chemotherapy during conditioning for stem cell transplants, where we have a phase 1/2 clinical trial using CKIT antibody (JSP 191) successfully in patients with SCID and Fanconi Anemia.

Recently we obtained a CLIN 2 grant from CIRM for using the JSP 191 antibody in patients with Fanconi Anemia.

My goal is to keep pursuing safety in stem cell transplantation for children who have life threatening disorders and keep pushing the envelop to save the precious lives.

CLINICAL TRIALS

- Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab, Recruiting
- Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation, Recruiting
- Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback, Recruiting
- A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant, Not Recruiting
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study, Not Recruiting
- Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients, Not Recruiting
- Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes, Not Recruiting
- Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease, Not Recruiting
- Gene Therapy for Fanconi Anemia, Complementation Group A, Not Recruiting
- JSP191 Antibody Targeting Conditioning in SCID Patients, Not Recruiting

- Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease, Not Recruiting
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant, Not Recruiting
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT, Not Recruiting
- Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients, Not Recruiting
- Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses, Not Recruiting
- Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders, Not Recruiting
- CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function, Not Specified
- PEACE: Pediatric Antifungal Comparative Effectiveness, Not Specified

Publications

PUBLICATIONS

- **Can we eliminate TBI/Busulfan and GVHD in Fanconi anemia transplantation? Results from a prospective haploidentical transplant approach**

  Bertaina, A., Czechowicz, A., Hiroshima, L., Kunte, N., Klinger, E., Saini, G., John, T., Alexander, J., Shyr, D., Shah, A., Klein, O., Boyel, J., Boelens, et al

  SPRINGERNATURE.2026: 122-123

- **Phase 1 gene therapy for patients with IPEX syndrome: preliminary in vivo data of the treatment with engineered Treg-like cell CD4^{LVFOXP3}**

  Alexander, J. L., Agarwal, R., Namjoshi, S., Ramachandran, A., Wang, B., Borna, S., Shah, S., Schaefer, K., Alkayed, A., Kuo, Y., Wani, P., Faseli, F., Kandar, et al

  SPRINGERNATURE.2026: 48-49

- **Begelomab (BEGESAND®) Salvages Steroid-Resistant Acute GVHD in Pediatric Patients.** *Journal of clinical medicine*

  Shyr, D., Chirieleison, S. M., Fernandez-Pol, S., Weinacht, K., Agarwal, R., Shah, A. J., Spinelli, M., Palmieri, R., Di Naro, A. F., Bertaina, A.

  2026; 15 (11)

- **Model-Based ATG Dosing Optimization in Ab Haplo-HSCT: Improved Pre-HSCT Exposure Consistency and Viral Infection Analysis**

  Shyr, D. C., Hiroshima, L., John, T. D., Barbarito, G., Agarwal, R., Alexander, J. L., Shah, A. J., Li, T., Chang, I., Arreola, V., Boelens, J., Bertaina, A.

  ELSEVIER SCIENCE INC.2026

- **T-allo10 Cell Addback Post-Abdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers**

  Bertaina, A., Bacchetta, R., Shyr, D. C., Saini, G., Lee, J., Agarwal, R., Klein, O. R., Wang, G., Margittai-Gotesman, D., Al Dakheel, A., Barbarito, G., Oppizzi, L., Limaye, et al

  ELSEVIER SCIENCE INC.2026: S99

- **THERAPEUTIC DOSES OF T-ALLO10 IMMUNOTHERAPY POST-ABDEPLETED HSCT ENHANCE IMMUNE RECONSTITUTION AND ACHIEVE 100% LEUKEMIA-FREE SURVIVAL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

  Bertaina, A., Bacchetta, R., Cepika, A., Shyr, D., Barbarito, G., Oppizzi, L., Chen, P., Saini, G., Lee, J., Kristovich, K., Agarwal, R., Klein, O., Melsop, et al

  SPRINGERNATURE.2025: 74-75

- **Hematopoietic stem cell transplantation using briquilimab (Anti-CD117 Antibody-Conditioning), immunosuppression and TCRαβ+ T-cell/ CD19+B-cell depleted haploidentical grafts in patients with fanconi anemia: An approach without irradiation, busulfan and calcineurin inhibitors.**

  Agarwal, R., Bertaina, A., Soco, C., Long-Boyle, J., Saini, G., Kunte, N., Hiroshima, L., Chan, Y., Willner, H., Krampf, M., Van Hentenryck, M., Perriman, R., Istomina, et al

  ELSEVIER.2025: 2432-2433

- **Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.** *Nature medicine*

  Agarwal, R., Bertaina, A., Soco, C., Long-Boyle, J. R., Saini, G., Kunte, N., Hiroshima, L., Chan, Y. Y., Willner, H., Krampf, M. R., Nofal, R., Barbarito, G., Sen, et al

  2025

- **Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials**
  Czechowicz, A. D., Sevilla, J., Booth, C., Zubicaray, J., Rio, P., Navarro, S., Cherry, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Rothe, M., Bastone, et al
  ELSEVIER.2024: 7463-7464

- **T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Aβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients**
  Bertaina, A., Bacchetta, R., Cepika, A., Shyr, D. C., Barbarito, G., Oppizzi, L., Chen, P., Saini, G., Lee, J., Kristovich, K., Agarwal, R., Klein, O., Melsop, et al
  ELSEVIER.2024: 3525-3526

- **Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts**
  Soco, C., Krampf, M. R., Chan, Y., Hoang, H., Kunte, N., Saini, G., Weinberg, K. I., Parkman, R., Bertaina, A., Agarwal, R., Porteus, M., Czechowicz, A. D.
  ELSEVIER.2024: 2015-2016

- **Lentiviral-Mediated Gene Therapy (RP-L102) for Fanconi Anemia [Group A], is Associated with Polyclonal Integration Patterns in the Absence of Conditioning**
  Czechowicz, A., Sevilla, J., Booth, C., Agarwal, R., Zubicaray, J., Rio, P., Navarro, S., Chetty, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Rothe, et al
  CELL PRESS.2024: 132

- **Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.** *Nature communications*
  Keller, M. D., Hanley, P. J., Chi, Y., Aguayo-Hiraldo, P., Dvorak, C. C., Verneris, M. R., Kohn, D. B., Pai, S., Davila Saldana, B. J., Hanisch, B., Quigg, T. C., Adams, R. H., Dahlberg, et al
  2024; 15 (1): 3258

- **Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCR α β + T-Cell/CD19+B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia**
  Agarwal, R., Bertaina, A., Soco, C., Saini, G., Kunte, N., Hiroshima, L., Chan, Y., Willner, H., Krampf, M. L., Nofal, R., Barbarito, G., Sen, S., Felber, et al
  AMER SOC HEMATOLOGY.2023

- **LENTIVIRAL-MEDIATED GENE THERAPY FOR PATIENTS WITH FANCONI ANEMIA [GROUP A]: UPDATED RESULTS FROM GLOBAL RP-L102 CLINICAL TRIALS**
  Sevilla, J., Booth, C., Czechowicz, A., Agarwal, R., Zubicaray, J., Rio, P., Chetty, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Choi, G., Zeini, et al
  SPRINGERNATURE.2023: 276-277

- **Effect of Testicular Boost in Children With Leukemia Receiving Total Body Irradiation and Stem Cell Transplant: A Single-Institution Experience.** *Advances in radiation oncology*
  Blomain, E. S., Jiang, A., Donaldson, S. S., Agarwal, R., Bertaina, A., Shyr, D., Eisenberg, M. L., Hoppe, R. T., Hiniker, S. M., Oh, J.
  2023; 8 (1): 101071

- **LENTIVIRAL-MEDIATED GENE THERAPY FOR FANCONI ANEMIA [GROUP A]: RESULTS FROM RP-L102 CLINICAL TRIALS**
  Czechowicz, A., Sevilla, J., Booth, C., Agarwal, R., Zubicaray, J., Rio, P., Navarro, S., Chetty, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Choi, et al
  WILEY.2023: S136-S137

- **Lentiviral-Mediated Gene Therapy for Fanconi Anemia [Group A]: Results from Global RP-L102 Clinical Trials**
  Czechowicz, A., Sevilla, J., Booth, C., Navarro, S., Agarwal, R., Zubicaray, J., Rio, P., Chetty, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Choi, et al
  CELL PRESS.2023: 118

- **Effect of Testicular Boost in Children With Leukemia Receiving Total Body Irradiation and Stem Cell Transplant: A Single-Institution Experience** *ADVANCES IN RADIATION ONCOLOGY*
  Blomain, E. S., Jiang, A., Donaldson, S. S., Agarwal, R., Bertaina, A., Shyr, D., Eisenberg, M. L., Hoppe, R. T., Hiniker, S. M., Oh, J.
  2023; 8 (1)

- **Precision Delivery of Steroids as a Rescue Therapy for Gastrointestinal Graft-versus-Host Disease in Pediatric Stem Cell Transplant Recipients** *Journal of Clinical Medicine*
  Levitte, s., Ganguly, A., Frolik, S., Guevara-Tique, A., et al
  2023; 12 (4229)

- **Hematopoietic and Immunological Assessment in Fanconi Anemia after Ex Vivo Lentiviral FANCA Gene Therapy with RP-L102**
  Nofal, R., Chan, Y., Sen, S., Figueroa, U., Willner, H., Felber, M., Krampf, M., Thongthip, S., Choi, G., Nicoletti, E., Schwartz, J. D., Weinberg, K., Rodriguez, et al
  AMER SOC HEMATOLOGY.2022: 7772-7773

- **Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials**
  Czechowicz, A., Sevilla, J., Booth, C., Agarwal, R., Zubicaray, J., Rio, P., Navarro, S., Chetty, K., O'Toole, G., Xu-Bayford, J., Ancliff, P., Sebastian, E., Choi, et al
  AMER SOC HEMATOLOGY.2022: 10646-10647

- **Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia.** *The New England journal of medicine*
  Bertaina, A., Grimm, P. C., Weinberg, K., Parkman, R., Kristovich, K. M., Barbarito, G., Lippner, E., Dhamdhere, G., Ramachandran, V., Spatz, J. M., Fathallah-Shaykh, S., Atkinson, T. P., Al-Uzri, et al
  2022; 386 (24): 2295-2302

- **Sequential hematopoietic stem cell transplantation (HSCT) followed by kidney transplant-3 children who received ABT-cell/CD19 B-cell depleted HSCT followed by kidney transplant from same parental donor are rejection free and immunosuppression free with donor specific tolerance > 1year post kidney transplant**
  Grimm, P., Lewis, D. B., Al-Uzri, A., Fathallah-Shaykh, S., Shah, A., Agarwal, R., Weinberg, K. I., Gallo, A., Concepcion, W., Bertaina, A.
  WILEY.2022

- **Functional Immune Tolerance Induced By Sequential Hematopoietic Stem Cell-Solid Organ Transplantation**
  Bertaina, A., Barbarito, G., Ramachandran, V. V., Kristovich, K., Lippner, E., Fathallah-Shaykh, S., Al-Uzri, A., Shah, A. J., Aubert, G., Slepicka, P., Oppizzi, L., Agarwal, R., Roncarolo, et al
  AMER SOC HEMATOLOGY.2021: 1818-+

- **Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials**
  Czechowicz, A., Sevilla, J., Agarwal, R., Booth, C., Zubicaray, J., Rio, P., Navarro, S., Ancliff, P., Sebastian, E., Beard, B. C., Law, K. M., Choi, G., Zeini, et al
  AMER SOC HEMATOLOGY.2021

- **Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.** *Science translational medicine*
  Chen, P. P., Cepika, A., Agarwal-Hashmi, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya Hernandez, L. C., Harre, N., Xu, L., Thomas, B. C., Ji, et al
  2021; 13 (617): eabf5264

- **Tissue-specific telomere shortening and degenerative changes in a patient with TINF2 mutation and dyskeratosis congenita.** *Human pathology (New York)*
  Roake, C. M., Juntilla, M., Agarwal-Hashmi, R., Artandi, S., Kuo, C. S.
  2021; 25

- **Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials**
  Czechowicz, A., Sevilla, J., Booth, C., Agarwal, R., Zubicaray, J., Rio, P., Navarro, S., Ancliff, P. J., Beard, B. C., Law, K. M., Choi, G., Zeini, M., Duran-Persson, et al
  CELL PRESS.2021: 339

- **Preclinical Safety and Efficacy Validation of CD4(LVFOXP3) Cells as an Innovative Cell-Based Gene Therapy Approach for IPEX Syndrome**
  Sato, Y., Nathan, A., Wright, J., Tate, K., Wani, P., Fazeli, F., Timnak, A., Bhatia, N., Agarwal-Hashmi, R., Bertaina, A., Roncarolo, M., Bacchetta, R.
  CELL PRESS.2021: 340

- **Adoptively Transferred, In Vitro-Generated Alloantigen-Specific Type 1 Regulatory T (Tr1) Cells Persist Long-Term In Vivo**
  Cepika, A., Chen, P. P., Agarwal, R., Saini, G., Louis, D. M., Amaya-Hernandez, L. C., Xu, L., Shiraz, P., Tate, K. M., Margittai, D., Bhatia, N., Meyer, E., Bertaina, et al
  CELL PRESS.2021: 73

- **CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products.** *Blood advances*
  Mantri, S., Reinisch, A., Dejene, B. T., Lyell, D. J., DiGiusto, D. L., Agarwal-Hashmi, R., Majeti, R., Weinberg, K. I., Porteus, M. H.
  2020; 4 (21): 5357–61

- **The Binns Program for Cord Blood Research: A novel model of cord blood banking for academic biomedical research.** *Placenta*
  Mantri, S., Sheikali, A., Binns, C., Lyell, D. J., DiGiusto, D. L., Porteus, M. H., Agarwal-Hashmi, R.
  2020; 103: 50–52

- **A beta T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders**
  Bertaina, A., Bacchetta, R., Lewis, D. B., Grimm, P. C., Shah, A. J., Agarwal, R., Concepcion, W., Czechowicz, A., Bhatia, N., Lahiri, P., Weinberg, K. I., Parkman, R., Porteus, et al
  ELSEVIER SCIENCE INC.2020: S288

- **The Binns Program for Cord Blood Research: A Novel Program for Cord Blood Procurement in an Academic Setting for Biomedical Research**
  Sheikali, A., Mantri, S., Lyell, D., Porteus, M., Agarwal, R.
  ELSEVIER SCIENCE INC.2020: S206

- **Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies**
  Agarwal, R., Bacchetta, R., Bertaina, A., Chen, P., Saini, G., Shiraz, P., Bhatia, N., Roncarolo, M.
  ELSEVIER SCIENCE INC.2020: S272–S273

- **Early Epigenetic Immune Quantification Following Alpha/Beta T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplant Correlates with CD4+T Cell Recovery at Day+100**
  Mayers, M., Schulze, J., Barbarito, G., Lakshmanan, U., Parkman, R., Weinberg, K. I., Chu, J., Agarwal, R., Roncarolo, M., Sachsenmaier, C., Bacchetta, R., Bertaina, A.
  ELSEVIER SCIENCE INC.2020: S305

- **Third-Party Virus-Specific T-Cell Infusion for Treatment of Refractory Viral Infections: Interim Results from PBMTC SUP1701**
  Keller, M. D., Hanley, P. J., Zhang, N., Tanna, J., Fatic, A., Lang, H., Ekanem, U., Sani, G. M., Aguayo-Hiraldo, P., Quigg, T. C., Verneris, M. R., Parikh, S., Dvorak, et al
  ELSEVIER SCIENCE INC.2020: S89–S90

- **Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1** *Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting*
  Cepika, A., Chen, P. P., Uyeda, M. J., Cieniewicz, B., Narula, M., Amaya, L., Louis, D. M., Xu, L., Ji, X., Bertaina, A., Agarwal-Hashmi, R., Davis, M. M., Meyer, et al
  2020: A159–A159

- **Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18y) With Early Relapse Hodgkin Lymphoma.** *Journal of pediatric hematology/oncology*
  Fernandez, K. S., Mavers, M., Marks, L. J., Agarwal, R.
  2019

- **Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency**
  Agarwal, R., Dvorak, C. C., Kwon, H., Long-Boyle, J. R., Prohaska, S. S., Brown, J. W., Le, A., Guttman-Klein, A., Weissman, I. L., Cowan, M. J., Logan, A. C., Weinberg, K. I., Parkman, et al
  AMER SOC HEMATOLOGY.2019

- **REGULATORY TYPE 1 T CELL INFUSION IN MISMATCHED RELATED OR UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR HEMATOLOGIC MALIGNANCIES**
  Agarwal, R., Bacchetta, R., Bertaina, A., Hu, J. C., Chen, P., Saini, G., Bhatia, N., Roncarolo, M.
  WILEY.2019

- **Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodgkin lymphoma.**
  Fernandez, K. S., Mavers, M., Chang-Halpenny, C. N., Titapiwatanakun, R., Baker, K., Pugmire, B., Tcheng, W., Agarwal-Hashmi, R.
  AMER SOC CLINICAL ONCOLOGY.2019

- **Chimerism Analysis in Pediatric Hematopoietic Stem Cell Transplantation for Non-Malignant Disorders**
  Mariano, L., Zhang, B., Kristovich, K., Agarwal-Hashmi, R., Roncarolo, M., Bertaina, A., Fernandez-Vina, M.
  ELSEVIER SCIENCE INC.2019

- **Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning**
  Agarwal, R., Dvorak, C. C., Prohaska, S., Long-Boyle, J., Kwon, H., Brown, J. M., Weinberg, K. I., Le, A., Guttman-Klein, A., Logan, A. C., Weissman, I. L., Digiusto, D., Cowan, et al
  ELSEVIER SCIENCE INC.2019

- **Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies**
  Agarwal, R., Bacchetta, R., Bertaina, A., Chu, J., Chen, P., Saini, G., Bhatia, N., Roncarolo, M.
  ELSEVIER SCIENCE INC.2019

- **Administration of BPX-501 Cells Following A beta T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL)**
  Galaverna, F., Ruggeri, A., Merli, P., Kapoor, N., Agarwal-Hashmi, R., Aquino, V., Jacobsohn, D. A., Qasim, W., Nemecek, E. R., Krishnamurti, L., Manwani, D., Kuhn, M., Locatelli, et al
  ELSEVIER SCIENCE INC.2019

- **Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017** *PEDIATRICS*
  Amatuni, G. S., Currier, R. J., Church, J. A., Bishop, T., Grimbacher, E., Nguyen, A., Agarwal-Hashmi, R., Aznar, C. P., Butte, M. J., Cowan, M. J., Dorsey, M. J., Dvorak, C. C., Kapoor, et al
  2019; 143 (2)

- **Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017.** *Pediatrics*
  Amatuni, G. S., Currier, R. J., Church, J. A., Bishop, T., Grimbacher, E., Nguyen, A. A., Agarwal-Hashmi, R., Aznar, C. P., Butte, M. J., Cowan, M. J., Dorsey, M. J., Dvorak, C. C., Kapoor, et al
  2019

- **Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience.** *Journal of adolescent and young adult oncology*
  Kozak, M. M., Yoo, C. H., Gutkin, P. M., von Eyben, R. n., Agarwal, R. n., Donaldson, S. S., Muffly, L. n., Hiniker, S. M.
  2019

- **Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.** *Blood advances*
  Li, C. n., Mathews, V. n., Kim, S. n., George, B. n., Hebert, K. n., Jiang, H. n., Li, C. n., Zhu, Y. n., Keesler, D. A., Boelens, J. J., Dvorak, C. C., Agarwal, R. n., Auletta, et al
  2019; 3 (17): 2562–70

- **Administration of BPX-501 Following alpha-T and B-Cell Depleted Haplo-HSCT in Children with Transfusion-Dependent Thalassemia**
  Galaverna, F., Pagliara, D., Manwani, D., Agarwal, R., Kuhn, M., Locatelli, F.
  AMER SOC HEMATOLOGY.2018

- **Related and Unrelated Donor Transplantation for beta Thalassemia Major: Results of an International Survey**
  Li, C., Mathews, V., George, B., Kim, S., Hebert, K., Jiang, H., Li, C., Zhu, Y., Keesler, D. A., Agarwal, R., Boelens, J., Dvorak, C. C., Auletta, et al
  AMER SOC HEMATOLOGY.2018

- **Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disrase (GvHD)**
  Elkeky, R., Jacobsohn, D. A., Agarwal, R., Naik, S., Kapoor, N., Krishnamurti, L., Slatter, M., Galaverna, F., Merli, P., Aldinger, M., Locatelli, F.
  AMER SOC HEMATOLOGY.2018

- **Administration of BPX-501 Cells Following A beta T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias**
  Locatelli, F., Ruggeri, A., Merli, P., Naik, S., Agarwal, R., Aquino, V., Jacobsohn, D. A., Qasim, W., Nemecek, E. R., Krishnamurti, L., Manwani, D., Kuhn, M., Kapoor, et al
  AMER SOC HEMATOLOGY.2018

- **Mapping the Cellular Heterogeneity of CD34-Selected Umbilical Cord Blood Products**
  Mantri, S., Reinisch, A., Weinberg, K., Lyell, D., DiGiusto, D., Agarwal-Hashmi, R., Porteus, M.

NATURE PUBLISHING GROUP.2018: 505–7

- **The Binns Program for Cord Blood Research: a novel program for cord blood procurement in an academic setting for biomedical research**
  Mantri, S., Lyell, D., DiGiusto, D., Porteus, M., Agarwal-Hashmi, R.
  NATURE PUBLISHING GROUP.2018: 787–88
- **The Cost of Hematopoietic Stem-Cell Transplantation in the United States** *AMERICAN HEALTH AND DRUG BENEFITS*
  Broder, M. S., Quock, T. P., Chang, E., Reddy, S. R., Agarwal-Hashmi, R., Arai, S., Villa, K. F.
  2017; 10 (7): 366–73
- **SINGLE INSTITUTION EXPERIENCE: COMPARISON OF HEPARIN VERSUS URSODIOL FOR PREVENTION OF VOD.**
  Shinn, L., Pinner, L., Kula, J., Kumar, P., Agarwal, R., Weinberg, K.
  ONCOLOGY NURSING SOC.2017
- **Anti-Fungal Prophylaxis Using Intermediate Dose Ambisome is Associated with Delayed Methotrexate Clearance in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation**
  Schultz, L., Kumar, K., Stone, S., Callard, E., Witkowski, J., Shinn, L., Pinner, L., Weinberg, K. I., Porteus, M. H., Agarwal, R., Shah, A. J., Kharbanda, S.
  ELSEVIER SCIENCE INC.2017: S297–S298
- **Anti-Fungal Prophylaxis Using Intermediate Dose Ambisome Is Associated with Delayed Methotrexate Clearance in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation**
  Schultz, L. M., Kumar, K., Stone, S., Callard, E., Witkowski, J., Shinn, L., Pinner, L., Franklin, S., Kula, J., Patel, N., Kumar, P., Weinberg, K. I., Porteus, et al
  AMER SOC HEMATOLOGY.2016
- **Invasive Fungal Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant** *JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY*
  Aftandilian, C., Weinberg, K., Willert, J., Kharbanda, S., Porteus, M., Maldonado, Y., Agarwal, R.
  2016; 38 (7): 574-580
- **Invasive Fungal Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant.** *Journal of pediatric hematology/oncology*
  Aftandilian, C., Weinberg, K., Willert, J., Kharbanda, S., Porteus, M., Maldonado, Y., Agarwal, R.
  2016; 38 (7): 574-580
- **Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens**
  Quock, T. P., Broder, M. S., Chang, E., Reddy, S. R., Arai, S., Agarwal-Hashmi, R., Villa, K. F.
  ELSEVIER SCIENCE INC.2016: S282
- **Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens**
  Quock, T. P., Broder, M. S., Chang, E., Reddy, S. R., Arai, S., Agarwal-Hashmi, R., Villa, K. F.
  AMER SOC HEMATOLOGY.2015
- **A Pediatric Case of T-Cell Prolymphocytic Leukemia** *PEDIATRIC BLOOD & CANCER*
  Mitton, B., Coutre, S., Willert, J., Schlis, K., Porteus, M., Kharbanda, S., Agarwal-Hashmi, R.
  2015; 62 (6): 1061-1062
- **A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor.** *Biology of blood and marrow transplantation*
  Mahadeo, K. M., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Killen, R., Kohn, D., Crooks, G. M., Shah, A. J., Kharbanda, S., Agarwal, R., Kapoor, N.
  2015; 21 (3): 440-444
- **Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution.** *Biology of blood and marrow transplantation*
  Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., Porteus, M., Weinberg, K. I., Agarwal-Hashmi, R.
  2015; 21 (2): 326-334
- **A Multidisciplinary Care Team Perspective on Children's Emotional Experience in Isolation for Stem Cell Transplantation** *2015 BMT Tandem Meetings*
  Savig, E. S., Gurevitch, J. H., Jackson, J. E., Malinowski, A., Ju, W. G., Leifer, L. J., Cohen, H. J., Sourkes, B. M., Agarwal-Hashmi, R.

2015: S180

- **Survival and neurocognitive outcomes after cranial or craniospinal irradiation plus total-body irradiation before stem cell transplantation in pediatric leukemia patients with central nervous system involvement.** *International journal of radiation oncology, biology, physics*
  Hiniker, S. M., Agarwal, R., Modlin, L. A., Gray, C. C., Harris, J. P., Million, L., Kiamanesh, E. F., Donaldson, S. S.
  2014; 89 (1): 67-74

- **Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.** *Biology of blood and marrow transplantation*
  Kharbanda, S., Smith, A. R., Hutchinson, S. K., McKenna, D. H., Ball, J. B., Lamb, L. S., Agarwal, R., Weinberg, K. I., Wagner, J. E.
  2014; 20 (4): 581-586

- **Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children.** *Biology of blood and marrow transplantation*
  DiCarlo, J., Agarwal-Hashmi, R., Shah, A., Kim, P., Craveiro, L., Killen, R., Rosenberg-Hasson, Y., Maecker, H.
  2014; 20 (3): 361-369

- **Durable Engraftment, Correction of Genetic Defects and Prevention of Veno-Occlussive Disease, Following Blood and Marrow Transplantation with an HLA-Matched Sibling DONOR, Using a Reduced Toxicity Conditioning Regimen with Busulfan, Reduced Dose Cyclophos**
  Mahadeo, K., Agarwal, R., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Shah, A. J., Tabba, L., Kapoor, N.
  ELSEVIER SCIENCE INC.2014: S83

- **Outcome in Pediatric Patients with a History of Fungal Disease Prior to Allogeneic Stem Cell Transplant**
  Aftandilian, C., Agarwal, R., Kharbanda, S., Weinberg, K. I.
  ELSEVIER SCIENCE INC.2014: S165

- **END Organ Disease in the Context of Human Herpes VIRUS 6 Viremia in Pediatric Allogeneic Hematopoietic STEM CELL Transplant Patients: A Case Series**
  Winestone, L., Agarwal, R., Montoya, J., Weinberg, K. I., Porteus, M. H., Pinsky, B., Soda, E., Waggoner, J., Tamaresis, J., Kharbanda, S.
  ELSEVIER SCIENCE INC.2014: S255

- **Survival and Neurocognitive Outcomes Following Cranial or Craniospinal Irradiation Plus Total Body Irradiation Prior to Transplantation in Children with CNS Leukemia**
  Hiniker, S. M., Agarwal, R., Modlin, L. A., Harris, J. P., Kiamanesh, E. E., Million, L., Gray, C. C., Donaldson, S. S.
  ELSEVIER SCIENCE INC.2014: S170–S171

- **Incidence and Mortality of Invasive Fungal Disease in Pediatric Patients after Allogeneic Stem Cell Transplant**
  Aftandilian, C., Agarwal, R., Kharbanda, S., Weinberg, K. I.
  ELSEVIER SCIENCE INC.2014: S165

- **Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
  Kwan, A., Church, J. A., Cowan, M. J., Agarwal, R., Kapoor, N., Kohn, D. B., Lewis, D. B., McGhee, S. A., Moore, T. B., Stiehm, E. R., Porteus, M., Aznar, C. P., Currier, et al
  2013; 132 (1): 140-U245

- **Bortezomib As a Treatment for Autoimmune Cytopenia After Bone Marrow Transplant** *BMT Tandem Meetings*
  Lalefar, N. R., Agarwal, R., Porteus, M. H., Kharbanda, S., Weinberg, K. I.
  ELSEVIER SCIENCE INC.2013: S177–S177

- **Autologous Transplantation for Hodgkin disease: A Tale of Two Eras** *BMT Tandem Meetings*
  Garfin, P. M., Luna-Fineman, S., Amylon, M., Kharbanda, S., Weinberg, K. I., Willert, J. R., Porteus, M., Link, M., Agarwal, R.
  ELSEVIER SCIENCE INC.2013: S247–S247

- **Single Institution Experience With Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and AYA Patients With Acute Leukemia** *BMT Tandem Meetings*
  Breese, E., Agarwal, R., Kharbanda, S., Breese, M., Amylon, M., Weinberg, K. I., Porteus, M., Dahl, G., Lacayo, N., Schlis, K., Willert, J. R.
  ELSEVIER SCIENCE INC.2013: S242–S243

- **Hematopoietic Cell Transplantation (HCT) for Treatment of Genetic Lymphohematopoietic Diseases for Patients Lacking a Fully Matched Sibling Donor Using a Novel Conditioning Regimen** *BMT Tandem Meetings*

Kharbanda, S., Agarwal, R., Miklos, D. B., Porteus, M., Amylon, M., Willert, J. R., Weinberg, K. I.
ELSEVIER SCIENCE INC.2013: S250–S251

- **High Risk Allogeneic Hematopoietic Cell Transplant (HCT) Patients with Any Level of Cytomegalovirus (CMV) Viremia Should Be Treated with Antiviral Therapy to Prevent Serious CMV Disease** *BMT Tandem Meetings*
  Winestone, L., Agarwal, R., Weinberg, K. L., Porteus, M., Willerts, J. R., Amylon, M., Kharbanda, S.
  ELSEVIER SCIENCE INC.2013: S312–S312

- **ENDOCRINE SEQUELAE OF STEM CELL TRANSPLANTATION**
  Barnum, J., Agarwal, R., Bachrach, L.
  WILEY PERIODICALS, INC.2012: 1022–23

- **THE CYTOKINE RESPONSE TO HEMATOPOIETIC STEM CELL TRANSPLANTATION** *40th Critical Care Congress*
  Kim, P., Agarwal, R., Shah, A., Craver, L., Killen, R., Rosenberg-Hasson, Y., DiCarlo, J.
  LIPPINCOTT WILLIAMS & WILKINS.2010: U80–U80

- **Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity** *BONE MARROW TRANSPLANTATION*
  Gramatges, M. M., Dvorak, C. C., Regula, D. P., Enns, G. M., Weinberg, K., Agarwal, R.
  2009; 44 (7): 449-450

- **Nontuberculous Mycobacteria Infections in Immunocompromised Patients Single Institution Experience** *JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY*
  Wei, M. C., Banaei, N., Yakrus, M. A., Stoll, T., Gutierrez, K. M., Agarwal, R.
  2009; 31 (8): 556-560

- **High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience** *BONE MARROW TRANSPLANTATION*
  Agarwal, R., Dvorak, C. C., Stockerl-Goldstein, K. E., Johnston, L., Srinivas, S.
  2009; 43 (7): 547-552

- **Delayed Platelet Engraftment and Early Increased Creatinine after Stem Cell Transplant Predicts Sustained Remission in Pediatric Leukemia**
  Sridhar, M., Dvorak, C. C., Agarwal, R., Schiffman, J. D.
  AMER SOC HEMATOLOGY.2008: 752

- **Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Dvorak, C. C., Agarwal, R., Dahl, G. V., Gregory, J. J., Feusner, J. H.
  2008; 14 (7): 824-830

- **SAFETY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN LESS THAN THREE YEARS OF AGE** *PEDIATRIC HEMATOLOGY AND ONCOLOGY*
  Dvorak, C. C., Wright, N. B., Wong, W. B., Kristovich, K. M., Matthews, E. W., Weinberg, K. I., Amylon, M. D., Agarwal, R.
  2008; 25 (8): 705-722

- **Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy** *BLOOD*
  Deeg, H. J., O'Donnell, M., Tolar, J., Agarwal, R., Harris, R. E., Feig, S. A., Territo, M. C., Collins, R. H., McSweeney, P. A., Copelan, E. A., Khan, S. P., Woolfrey, A., Storer, et al
  2006; 108 (5): 1485-1491

- **Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus** *BONE MARROW TRANSPLANTATION*
  Dvorak, C. C., Callard, E., Agarwal, R.
  2006; 38 (3): 253-254

- **Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
  Dvorak, C. C., Steinbach, W. J., Brown, J. M., Agarwal, R.
  2005; 36 (7): 621-629

- **High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices** *45th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
  Lieskovsky, Y. E., Donaldson, S. S., Torres, M. A., Wong, R. M., Amylon, M. D., Link, M. P., Agarwal, R.
  AMER SOC CLINICAL ONCOLOGY.2004: 4532–40

- **Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy** *JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY*
  DiCarlo, J. V., Alexander, S. R., Agarwal, R., Schiffman, J. D.
  2003; 25 (10): 801-805

- **Early CVVH increases survival from bone marrow transplant ARDS**
  DiCarlo, J. V., Alexander, Agarwal-Hashmi, R., Schiffman, J. D.
  INT PEDIATRIC RESEARCH FOUNDATION, INC.2003: 274A–275A

- **Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation** *BONE MARROW TRANSPLANTATION*
  Morris, J. D., Harris, R. E., Hashmi, R., SAMBRANO, J. E., Gruppo, R. A., Becker, A. T., Morris, C. L.
  1997; 20 (10): 871-878

- **Retroviral transduction of CD34-enriched hematopoietic progenitor cells under serum-free conditions** *HUMAN GENE THERAPY*
  Sekhar, M., Kotani, H., Doren, S., Agarwal, R., McGarrity, G., DUNBAR, C. E.
  1996; 7 (1): 33-38

- **LONG-TERM CULTURE OF CHRONIC MYELOGENOUS LEUKEMIA MARROW-CELLS ON STEM-CELL FACTOR-DEFICIENT STROMA FAVORS BENIGN PROGENITORS** *BLOOD*
  Agarwal, R., Doren, S., Hicks, B., DUNBAR, C. E.
  1995; 85 (5): 1306-1312

- **SPLENIC AND HEPATIC PELIOSIS - MR FINDINGS** *AMERICAN JOURNAL OF ROENTGENOLOGY*
  MAVES, C. K., CARON, K. H., Bisset, G. S., Agarwal, R.
  1992; 158 (1): 75-76